The NSD2 protein is recruited to the ERα promoter by BRD3/4 and facilitates ERα expression, although inhibition of BRD3/4 via JQ1 suppresses the ERα signaling pathway and growth of tamoxifen-resistant BC cells by disrupting the BRD/WHSC1/ERα axis (Feng et al., 2014). This evidence concerns the gene NSD2 and breast cancer.